

September 25, 2018

Aryn Knight, BS, CCRP
Assistant Administrative Director
Center for Clinical Research
Texas Heart Institute
6770 Bertner Avenue, MC 4-266
Houston, TX 77030

Dear Ms. Knight,

This letter is to inform you that Proxima Clinical Research, Inc. is working with Saranas, Inc. on a research study concerning a novel medical device that is believed to be able to detect internal bleeding during an endovascular procedure. We are the Contract Research Organization (CRO) of record and currently targeting Texas Heart Institute (THI) as a clinical research site for a medical device study entitled "*A clinical study to evaluate the safety and Accuracy of the Saranas Early Bird™ Bleed monitoring system for the detection of endovascular procedure related bleeding events.*" The principal investigator (PI) of the trial is Philippe Genereux, MD, at the Atlantic Center for Research located in Morristown New Jersey.

Texas Heart Institute is one of up to ten research sites in this study, and one of two selected in the Texas Medical Center. Dr. Joggy George will serve as the Principal Investigator for this study.

As required by THI local institutional policies, we are disclosing that THI is a minority shareholder of Saranas, Inc. The total shares that THI owns of Saranas is less than 10% on a fully diluted basis.

This potential conflict is minimized by utilizing a 3rd party CRO (Proxima) to collect and monitor data, utilizing an IRB, and distributing patients that will be tested across several other outside institutions. In other words, the number of patients enrolled by THI in this study will be a minority of the overall total number of patients.

Please feel free to provide this disclosure to any and all relevant departments and parties at THI and let us know if you require anything further.

Sincerely,



J. Kevin Coker, JD, MPH, MS
CEO, Proxima Clinical Research

CC: Zaffer Syed, MS, MBA - President & CEO Saranas, Inc.

